No Data
These 4 Measures Indicate That Bristol-Myers Squibb (NYSE:BMY) Is Using Debt Reasonably Well
Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August
Segal Trials Plays Key Role in FDA Approval of COBENFY, A New Era in Schizophrenia Treatment
Barclays Adjusts Price Target on Bristol-Myers Squibb to $43 From $42, Maintains Underweight Rating
Bristol-Myers Squibb Says FDA Approves Perioperative Treatment of Neoadjuvant Opdivo in NSCLC
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo (Nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
No Data
No Data
